c-Myc Is Required for Maintenance of Glioma Cancer Stem Cells Authors: Jialiang Wang, Hui Wang, Zhizhong Li, Qiulian Wu, Justin D. Lathia, Roger E. McLendon, Anita B. Hjelmeland, Jeremy N. Rich Published: 2008, PLOS ONE DOI: 10.1371/journal.pone.0003769 ABSTRACT Malignant gliomas rank among the most lethal cancers. Gliomas display a striking cellular heterogeneity with a hierarchy of differentiation states. Recent studies support the existence of cancer stem cells in gliomas that are functionally defined by their capacity for extensive self-renewal and formation of secondary tumors that phenocopy the original tumors. As the c-Myc oncoprotein has recognized roles in normal stem cell biology, we hypothesized that c-Myc may contribute to cancer stem cell biology as these cells share characteristics with normal stem cells. Based on previous methods that we and others have employed, tumor cell populations were enriched or depleted for cancer stem cells using the stem cell marker CD133 (Prominin-1). We characterized c-Myc expression in matched tumor cell populations using real time PCR, immunoblotting, immunofluorescence and flow cytometry. Here we report that c-Myc is highly expressed in glioma cancer stem cells relative to non-stem glioma cells. To interrogate the significance of c-Myc expression in glioma cancer stem cells, we targeted its expression using lentivirally transduced short hairpin RNA (shRNA). Knockdown of c-Myc in glioma cancer stem cells reduced proliferation with concomitant cell cycle arrest in the G 0 /G 1 phase and increased apoptosis. Non-stem glioma cells displayed limited dependence on c-Myc expression for survival and proliferation. Further, glioma cancer stem cells with decreased c-Myc levels failed to form neurospheres in vitro or tumors when xenotransplanted into the brains of immunocompromised mice. These findings support a central role of c-Myc in regulating proliferation and survival of glioma cancer stem cells. Targeting core stem cell pathways may offer improved therapeutic approaches for advanced cancers. INTRODUCTION The emerging cancer stem cell model suggests that tumors are organized in a hierarchy with a subpopulation of cancer stem cells responsible for tumor maintenance and progression. Cancer stem cells are highly tumorigenic and phenocopy the original tumors in rodent xenograft models. Depletion of the cancer stem cell population greatly impairs the potential to initiate xenograft tumor formation of the bulk tumors [1] , [2] . The cancer stem cell population also contributes to solid tumor angiogenesis [3] , metastasis [4] , and resistance to chemotherapy and radiotherapy [3] , [5] , [6] , [7] , [8] , [9] . While this model has been validated in a growing list of haematopoietic and solid tumors, the molecular signaling pathways orchestrating the biology of cancer stem cells remain to be elucidated. The c-Myc oncoprotein has been extensively studied for its instrumental role in proliferation and growth of normal and neoplastic cells. Deregulated c-Myc is found in diverse human tumors and is often associated with advanced malignancy and poor prognosis [10] . As c-Myc has been recently recognized as an important regulator of stem cell biology, it may serve as a link connecting malignancy and “stemness” [11] . In either normal or transformed cells, c-Myc alone activates an embryonic stem cell-like transcriptional module, which strongly correlates with tumor metastasis and mortality [12] . Ectopic c-Myc expression in transformed human keratinocytes dramatically increases the cancer stem cell fraction and enhances tumorigenicity [12] . Introduction of c-Myc with other transcription factors (including Oct3/4, Sox2, and Klf4) generates induced pluripotent stem (iPS) cells from differentiated cells [13] . Excluding c-Myc from this combination without eliminating endogenous c-Myc expression, drastically reduces the efficiency of iPS cell production [13] , [14] , [15] , [16] . While all of these data suggest a role for c-Myc in maintaining stem cells, other functions of c-Myc in regulating stem cell biology have also been described. Conditional knockout of c-Myc in mouse bone marrow does not prevent proliferation or self-renewal of haematopoietic stem cells [17] . It rather results in accumulation of haematopoietic stem cells in bone marrow, suggesting that c-Myc specifically controls the interaction between haematopoietic stem cells and their niches. Additionally, over-expression of c-Myc-estrogen receptor fusion protein in human epidermal stem cells drives differentiation rather than proliferation [18] , [19] . Because of the recognized functions of c-Myc in both normal stem cell biology and neural malignancy, we investigated the role of c-Myc in human glioma cancer stem cells. Gliomas are the most common primary intrinsic tumor type of the central nervous system. High grade gliomas (World Health Organization grades III and IV) are among the most lethal human malignancies [20] . In glioma, c-Myc expression correlates with the grade of malignancy [21] . Expression of c-Myc driven by the glial fibrillary acidic protein (GFAP)-promoter in developing mouse astroglia induces tumors that resemble human glioblastoma multiforme [22] . In this mouse model, the tumor mass contains fast dividing subpopulation that express c-Myc and relatively quiescent tumor cells that lack c-Myc expression [22] . We have now determined that the glioma cancer stem cells expressed higher levels of c-Myc relative to matched non-stem tumor cells and the activity of c-Myc is required for proliferation, growth, and survival of glioma cancer stem cells. Loss of c-Myc abolished xenograft formation by glioma cancer stem cells, underscoring a key role of c-Myc in glioma cancer stem cell maintenance. RESULTS To investigate the biological functions of c-Myc in regulation of glioma cancer stem cells, we first determined expression of c-Myc in these cells. Short term cultures enriched or depleted for cancer stem cells were derived from human brain tumor specimens using CD133 selection and characterized as we have previously demonstrated [9] . Quantitative real-time PCR revealed that CD133+ glioma cells expressed higher c-Myc mRNA levels than matched CD133− glioma cells ( Figure 1A ). The differential mRNA levels translated into higher levels of c-Myc protein in CD133+ glioma cells than matched CD133− cells ( Figure 1B ). Consistent with prior reports [23] , [24] , the cancer stem cell-enriched fractions also expressed high levels of Olig2, a marker of adult neural multipotent progenitors ( Figure 1B ). To directly measure the expression of c-Myc in human brain tumors, we further evaluated c-Myc expression by flow cytometry in both CD133+ and CD133− fractions of glioma cells acutely isolated from human surgical biopsy specimens without in vitro culture ( Figure 1C ). Approximately half of the CD133+ cells were high in c-Myc expression, whereas nearly 90% CD133− cells expressed low levels of c-Myc ( Figure 1D ). We further examined c-Myc expression in glioma cancer stem cells using sections generated from acutely frozen human glioma surgical specimens. Because co-staining with CD133 was not compatible with antigen retrieval method required for c-Myc staining, we co-stained c-Myc with another neural stem cell marker Nestin. Greater than 90% of Nestin positive glioma cells were also c-Myc positive ( Figure 1E ). These data suggest that c-Myc is highly expressed in glioma cancer stem cells. (A) CD133− and CD133+ cells were isolated from glioma surgical biopsy specimens passaged short-term in immunocompromised mice and briefly cultured. Total RNA was isolated from both CD133− and CD133+ cells. cDNA was prepared by reverse transcription. Expression of c-Myc was then determined by quantitative real-time PCR and normalized to β-actin and HPRT1. Relative mRNA levels of c-Myc in CD133− cells were assigned a value of 1. Data are represented as mean±S.E.M in this and all subsequent graphs (#: p<0.001). (B) Total cellular lysates were resolved by SDS-PAGE. Protein levels of c-Myc and Olig2 were determined by immunoblotting. Actin was blotted as the loading control. (C) Glioma cells were isolated directly from human surgical biopsy specimens, fixed in 4% paraformaldehyde following dissociation, labeled with anti-CD133-APC and anti-c-Myc-FITC, and subjected to FACS analysis. (D) Percentage of cells expressing high levels of c-Myc within either the CD133− fraction or the CD133+ fraction was demonstrated (#: p<0.001). (E) Sections of freshly frozen human glioma surgical biopsy specimens were fixed and co-stained for c-Myc (green) and Nestin (red). Nuclei were counterstained with Hoechst 33342. Representative images (630×) were demonstrated. C-MYC REGULATES CELL CYCLE PROGRESSION AND PROLIFERATION OF GLIOMA CANCER STEM CELLS c-Myc plays a key role in regulating cellular proliferation by controlling the expression of cell cycle proteins. To interrogate the role of c-Myc in the cell cycle of glioma cancer stem cells, we targeted c-Myc expression by infection with lentivirus expressing shRNA specific to c-Myc. Two different shRNAs efficiently decreased c-Myc expression in both CD133− and CD133+ glioma cells as shown by quantitative real-time PCR and immunoblotting ( Figure 2A and 2B ). Similar results were found in another tumor specimen (T4597, data not shown). Depletion of c-Myc significantly reduced the S phase cell population with concomitant increase of the G 0 /G 1 cell population in CD133+ cells (p<0.001, Figure 3 ). In contrast, CD133− cells displayed a lower rate of proliferation with a smaller S phase population than matched CD133+ cells ( Figure 3 and data not shown), and the cell cycle progression in CD133− cells was not significantly altered by knockdown of c-Myc. Regulation of the cell cycle by c-Myc is commonly mediated through transcriptional regulation of the cyclins and the cyclin-dependent kinase inhibitors, including cyclins D 1 , D 2 , and E and p21 WAF1/CIP1 [26] , [27] ( http://www.myc-cancer-gene.org ). Attenuating c-Myc expression specifically reduced cyclin D 1 protein levels, but not cyclins D 2 or E, in CD133+ cells ( Figure 2B ). Additionally, p21 WAF1/CIP1 protein levels were upregulated in cancer stem cells depleted of c-Myc, whereas p53 levels were only moderately altered ( Figure 2B ). Quantitative real-time PCR showed a similar pattern of cyclin D 1 and p21 WAF1/CIP1 regulation at mRNA levels by c-Myc in CD133+ cells, suggesting c-Myc regulated these two genes at the level of transcription. In striking contrast, cyclin D 1 and p21 WAF1/CIP1 were minimally altered by knocking down c-Myc at either the mRNA or protein levels in CD133− cells. Notably, basal cyclin D 1 levels were higher in CD133+ cells than matched CD133− cells, whereas cyclin D 2 and cyclin E levels were higher in CD133− cells, suggesting that cyclin D 1 , but not cyclins D 2 or E, is critical for the G 1 /S transition in CD133+ glioma cells. Taken together, these results suggest that c-Myc regulates cell cycle progression in glioma cancer stem cells, at least partially, through controlling expression of cyclin D 1 and p21 WAF1/CIP1 . (A) Early passage (85%) of CD133− cells were c-Myc-low ( Figure 1D ). Similar co-expression of c-Myc and a stem cell marker, Nestin, was identified directly on human surgical biopsy specimen sections ( Figure 1E ). Notably, glioma cancer stem cells expressing c-Myc shRNA still retained residual levels of c-Myc protein ( Figure 2B, lanes 5 and 6 ) that were higher than the c-Myc levels found in CD133− cells expressing non-targeting shRNA ( Figure 2B, lane 1 ). Nonetheless, the reduced levels of c-Myc were incapable of supporting proliferation, growth, survival, and tumorigenesis of glioma cancer stem cells. A recent mouse model of T-cell lymphoma using conditionally expressed c-Myc also suggest that certain threshold level of c-Myc is required to maintain the tumor phenotype [42] . Collectively, our results highlight a necessary requirement of high c-Myc expression in glioma cancer stem cells. Cancer stem cells have been proposed as slowly cycling cells, like their somatic stem cell counterparts [43] . Rapid expansion of tumors is then dependent on the fast dividing progenitor cells. The slow cell cycle may provide cancer stem cells a protective mechanism against certain therapeutic approaches that target rapid proliferating cells. For example, in human acute myelogenous leukemia, the quiescent leukemia stem cells are resistant to chemo-drugs that dependent on cell cycle [44] . Nevertheless, characteristics of cancer stem cells may not be necessarily uniform across different cancer types, and the biology of cancer stem cells may change throughout different stages of tumor development. In brain tumors, Singh and co-workers first demonstrated that only the CD133+ cancer stem cell population proliferate in vitro when acutely isolated from human surgical biopsy specimens [28] , [29] . These results were similar to the highly proliferative cancer stem cells that were characterized in a RAS-induced zebrafish embryonal rhabdomyosarcoma [45] . In the present study, we determined that the CD133+ glioma cells contained a higher percentage of S phase cells and grew faster in vitro than matched CD133− cells ( Figures 3 and 4 ). We also found that proliferation and growth of glioma cancer stem cells were severely impaired upon knockdown of c-Myc, but importantly, the cell cycle progression of CD133− glioma cells were relatively insensitive to loss of c-Myc. The transcriptional programs regulated by c-Myc remain poorly defined and dependent on cell state [26] , [46] , but include induction of cyclin D 1 [47] and repression of the p21 WAF1/CIP1 cyclin-dependent kinase inhibitor [48] , [49] . Consistently, expression of cell cycle regulators downstream of c-Myc, including p21 WAF1/CIP1 and cyclin D 1 , was altered in glioma cancer stem cells following c-Myc knockdown, but not in the CD133− cells. These data uncover a specific role of c-Myc and its downstream target genes in regulating proliferation and growth of the CD133+ glioma cancer stem cells. Apoptosis can be induced by aberrant expression of certain oncogenes, such as c-Myc and E2F1, which may act as a “fail-safe” mechanism to eradicate potential cellular transformation [33] , [50] . Apoptosis induced by c-Myc can be mediated through activation of the ARF-MDM2-p53 pathway, or by activating death receptors, such as CD95/Fas [33] . However, deregulation of c-Myc is common in human tumors and is an indicator of poor prognosis because tumors are well equipped with various anti-apoptosis mechanisms which can neutralize the apoptotic pressure introduced by c-Myc. Tumorigenesis in c-Myc transgenic mouse models is accelerated if combined with other anti-apoptosis genetic alterations, such as overexpression of Bcl-2 [51] or Bmi1 [52] , or disrupting the ARF-MDM2-p53 pathway [53] . Further, it has been directly demonstrated that sustained c-Myc activity is required for tumor maintenance in a variety of conditional transgenic mouse models. These models show that inactivation of c-Myc almost inevitably results in tumor regression regardless of tumor type with concomitant growth inhibition, differentiation, and apoptosis (reviewed in [54] ). In some cases, such as osteosarcoma [55] and skin tumors [56] , brief inactivation of c-Myc is sufficient to induce sustained tumor regression. However, the dependence on c-Myc can be tumor-type specific. In certain conditional transgenic models, reactivation of c-Myc after transient disruption restores tumor growth [57] , which may involve activation of dormant cancer stem cells. Alternatively, tumors may relapse in a portion of animals even in the absence of c-Myc activity, suggesting that cancer stem cells may have accumulated additional mutations to compensate loss of c-Myc [58] , [59] , [60] . The sustained tumor regression may be associated with complete eradication of cancer stem cells following inactivation of c-Myc, whereas cancer stem cells may survive and/or escape c-Myc dependence in recurrent tumors. Our study demonstrated a marked induction of apoptosis following c-Myc knockdown in the cancer stem cell population ( Figure 4 ), and the cancer stem cells depleted of c-Myc expression failed to develop orthotopic xenograft tumors in nude mice ( Figure 6 ). Of particular interest, survival of the non-stem glioma cells was not dependent on sustained expression of c-Myc. In a number of recent studies in other cancer models, targeting c-Myc expression impaired cellular proliferation and induced senescence [61] , [62] , [63] . These models may represent outcome of loss of c-Myc in more homogeneous cancer cell populations, particularly genetically engineered models driven by overexpression of c-Myc. Our study has important implications as targeting c-Myc has unique benefits specific to cellular compartments in models representing cellular heterogeneity. Although targeting c-Myc was sufficient to prevent tumor growth in our studies, the dichotomous effects of c-Myc inhibition that we have detected may support the need to simultaneously target the non-stem cell tumor populations to achieve clinical efficacy. Thus, c-Myc as a molecular target must be approached with sophistication as the majority of tumor cells may demonstrate limited therapeutic responses but a critical tumor population – the cancer stem cells – may be inhibited or killed to improve overall tumor control and decrease resistance to other therapies. Taken together, our study suggests that the proliferation, growth, and survival of glioma cancer stem cells are critically dependent on c-Myc expression and that targeting c-Myc pathways may significantly improve brain tumor therapy. MATERIALS AND METHODS Primary glioma surgical biopsy specimens were obtained from patients undergoing resection for newly diagnosed or recurrent glioma in accordance with protocols approved by the Duke University Medical Center Institutional Review Board. Written consent to utilize excess tissue for research was obtained from each patient, and de-identified tissues were used for all studies. Cells were isolated from human glioma surgical specimens and cultured as previously described [3] , [9] . Briefly, tumors were dissected, washed in Earle's balanced salt solution, digested with papain, titurated, and filtered. Red blood cells were lysed in diluted phosphate buffered saline solution (0.25×). Glioma cells were then cultured overnight in stem cell media (neurobasal media supplemented with B27 and epidermal growth factor and basic fibroblast growth factor (Invitrogen, Carlsbad, CA) at 20 ng/ml) prior to cell sorting for recovery of cellular surface antigens. The CD133− and CD133+ fractions were separated by magnetic sorting using the CD133 Microbead kit (Miltenyi Biotec, Auburn, CA). CD133− cells were maintained in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (Invitrogen), but were cultured in stem cell media at least 24 hours prior to experiments to control differences in cell media. T3359, T3832, T4302 and T4597 were originally derived from human glioma surgical biopsy specimens and were maintained as subcutaneous xenografts in athymic BALB/c nude mice. ANTIBODIES The antibodies used were as follows: Mouse anti-c-Myc antibody (9E10), FITC-conjugated rabbit anti-c-Myc antibody (A14), mouse anti-cyclin D 1 antibody (DCS-6), rabbit anti-cyclin D 2 antibody (H-289), mouse anti-cyclin E antibody (13A3), mouse anti-p53 antibody (DO-1) were from Santa Cruz Biotechnology (Santa Cruz, CA); APC-conjugated mouse anti-CD133 antibody (AC133-1) was from Miltenyi; goat anti-Olig2 antibody was from R&D Systems (Minneapolis, MN); mouse anti-p21 WAF1/CIP1 antibody was from Cell signaling Technology (Danvers, MA); mouse anti-actin antibody was from Millipore (Billerica, MA). IMMUNOFLUORESCENT STAINING Freshly frozen human glioma surgical biopsy samples were processed and 10 micron sections were mounted on glass slides in accordance with the Duke University Medical Center Institutional Review Board. Prior to staining, the sections were fixed in 4% paraformaldehyde at room temperature for 10 minutes, boiled in 10 mM sodium citrate solution (pH = 6.0) for 10 minute, and were blocked in 10% normal goat serum (Sigma-Aldrich, St. Louis, MO) and 0.1% Triton X-100 for 30 minutes at room temperature. Sections were incubated with primary antibodies at 4°C overnight and secondary antibodies at room temperature for 45 minutes, and then were counterstained with Hoechst 33342 (Invitrogen). For fluorescence imaging, confocal z-stacks were taken by a 63× water immersion objective lens on a Leica SP-5 microscope using sequential scans (blue-red, green). The following antibodies were used: mouse anti-c-Myc (Santa Cruz, 1∶50), rabbit anti-Nestin (Abcam, Cambridge, MA, 1∶100); goat anti-mouse IgG 1 Alexa 488 (Invitrogen, 1∶200), goat anti-rabbit IgG Alexa 568 (Invitrogen, 1∶200). LENTIVIRUS PRODUCTION The lentiviral vectors directing expression of shRNA specific to c-Myc (TRCN0000039640 and TRCN0000039641) or a non-targeting shRNA (SHC002) (Sigma-Aldrich) were co-transfected with the packaging vectors psPAX2 and pCI-VSVG (Addgene, Cambridge, MA) into 293FT cells by lipofectamine 2000 (Invitrogen) to produce virus. Two days following transfection, viral supernatants were collected, filtered, and concentrated by ultracentrifugation at 100,000 g for 3 hours. FACS ANALYSIS Glioma cells isolated from surgical biopsy specimens were fixed in 4% paraformaldehyde, and permeablized in 0.1% Triton X-100 for 10 minutes. Cells were then washed twice in PBS and labeled with APC-conjugated CD133 antibody (AC133, 1∶11) and FITC-conjugated c-Myc antibody (A14, 1∶50) for 1 hour at room temperate. Cells were then washed once in PBS and sorted. REAL-TIME PCR Total RNA was prepared using the RNeasy kit (Qiagen, Valencia, CA), and reverse transcribed into cDNA by iScript cDNA synthesis kit (BioRad, Hercules, CA). Real-time PCR was performed on an ABI 7900HT system using SYBR-Green Mastermix (SuperArray, Frederick, MD). PCR products were verified by melting curves and were also run on a 2% agarose gel to confirm the appropriate size. The threshold cycle ( C T ) values for each gene were normalized to expression levels of β-Actin and HPRT1 (hypoxanthine phosphoribosyltransferase 1). The primers used were as follows: β-Actin, forward 5′-AGAAAATCTGGCACCACACC-3′ ; reverse 5′-AGAGGCGTACAGGGATAGCA-3′ ; HPRT1, forward 5′-TGACCTTGATTTATTTTGCATACC-3′ ; reverse 5′-CGAGCAAGACGTTCAGTCCT-3′ ; c-Myc, forward 5′-TCAAGAGGCGAACACACAAC-3′ ; reverse 5′-GGCCTTTTCATTGTTTTCCA-3′ ; cyclin D1, forward 5′-CCGCTGGCCATGAACTACCT-3′ ; reverse 5′-ACGAAGGTCTGCGCGTGTT-3′ ; cyclin D2, forward 5′-TGGAGCTGCTGTGCCACG-3′ ; reverse 5′-GTGGCCACCATTCTGCGC-3′ ; p21 WAF1/CIP1 , forward 5′-TCACTGTCTTGTACCCTTGTGC-3′ ; reverse 5′-GGCGTTTGGAGTGGTAGAAA-3′ . GROWTH CURVE AND NEUROSPHERE FORMATION ASSAY Both CD133− and CD133+ glioma fractions of glioma cells were infected by the control lentivirus or lentivirus directing expression of c-Myc shRNA and were selected with 1 µg/ml puromycin for 2 days. 5000 CD133− cells or 1000 CD133+ cells were plated in 96-well plate in triplicate. Cell number was measured for 5 consecutive days using the CellTiter-Glo assay kit (Promega, Madison, MI). Additionally, 100 or 10 CD133+ cells were seeded per well in 24-well tissue culture plates. Eight wells were plated for each group. Seven days after plating, neurospheres containing more than 20 cells were scored. INTRACRANIAL XENOGRAFT FORMATION ASSAY 5000 T3359 CD133+ cells lentivirally infected and selected for expression of the puromycin marker were implanted into brains of athymic BALB/c nude mice under a Duke University Institutional Animal Care and Use Committee–approved protocol. Mice were maintained for 100 days or until development of neurologic signs. Brains of euthanized mice were collected, fixed in 4% paraformaldehyde, paraffin embedded, sectioned, and subjected to hematoxylin and eosin staining. REFERENCES [1] Jin L Hope KJ Zhai Q Smadja-Joffe F Dick JE 2006 Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12 1167 1174 [2] Ito K Bernardi R Morotti A Matsuoka S Saglio G 2008 PML targeting eradicates quiescent leukaemia-initiating cells. Nature 453 1072 1078 [3] Bao S Wu Q Sathornsumetee S Hao Y Li Z 2006 Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 66 7843 7848 [4] Hermann PC Huber SL Herrler T Aicher A Ellwart JW 2007 Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1 313 323 [5] Li X Lewis MT Huang J Gutierrez C Osborne CK 2008 Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100 672 679 [6] Zhang M Behbod F Atkinson RL Landis MD Kittrell F 2008 Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res 68 4674 4682 [7] Liu G Yuan X Zeng Z Tunici P Ng H 2006 Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5 67 [8] Todaro M Alea MP Di Stefano AB Cammareri P Vermeulen L 2007 Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 1 389 402 [9] Bao S Wu Q McLendon RE Hao Y Shi Q 2006 Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444 756 760 [10] Vita M Henriksson M 2006 The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol 16 318 330 [11] Murphy MJ Wilson A Trumpp A 2005 More than just proliferation: Myc function in stem cells. Trends Cell Biol 15 128 137 [12] Wong DJ Liu H Ridky TW Cassarino D Segal E 2008 Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2 333 344 [13] Takahashi K Yamanaka S 2006 Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126 663 676 [14] Nakagawa M Koyanagi M Tanabe K Takahashi K Ichisaka T 2008 Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol 26 101 106 [15] Knoepfler PS 2008 Why myc? An unexpected ingredient in the stem cell cocktail. Cell Stem Cell 2 18 21 [16] Takahashi K Tanabe K Ohnuki M Narita M Ichisaka T 2007 Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131 861 872 [17] Wilson A Murphy MJ Oskarsson T Kaloulis K Bettess MD 2004 c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation. Genes Dev 18 2747 2763 [18] Waikel RL Kawachi Y Waikel PA Wang XJ Roop DR 2001 Deregulated expression of c-Myc depletes epidermal stem cells. Nat Genet 28 165 168 [19] Gandarillas A Watt FM 1997 c-Myc promotes differentiation of human epidermal stem cells. Genes Dev 11 2869 2882 [20] Louis DN 2006 Molecular pathology of malignant gliomas. Annu Rev Pathol 1 97 117 [21] Herms JW von Loewenich FD Behnke J Markakis E Kretzschmar HA 1999 c-myc oncogene family expression in glioblastoma and survival. Surg Neurol 51 536 542 [22] Jensen NA Pedersen KM Lihme F Rask L Nielsen JV 2003 Astroglial c-Myc overexpression predisposes mice to primary malignant gliomas. J Biol Chem 278 8300 8308 [23] Bao S Wu Q Li Z Sathornsumetee S Wang H 2008 Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res In press [24] Ligon KL Huillard E Mehta S Kesari S Liu H 2007 Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron 53 503 517 [25] Panchision DM Chen HL Pistollato F Papini D Ni HT 2007 Optimized flow cytometric analysis of central nervous system tissue reveals novel functional relationships among cells expressing CD133, CD15, and CD24. Stem Cells 25 1560 1570 [26] Dang CV O'Donnell KA Zeller KI Nguyen T Osthus RC 2006 The c-Myc target gene network. Semin Cancer Biol 16 253 264 [27] Bouchard C Staller P Eilers M 1998 Control of cell proliferation by Myc. Trends Cell Biol 8 202 206 [28] Singh SK Hawkins C Clarke ID Squire JA Bayani J 2004 Identification of human brain tumour initiating cells. Nature 432 396 401 [29] Singh SK Clarke ID Terasaki M Bonn VE Hawkins C 2003 Identification of a cancer stem cell in human brain tumors. Cancer Res 63 5821 5828 [30] Kaptein JS Lin CK Wang CL Nguyen TT Kalunta CI 1996 Anti-IgM-mediated regulation of c-myc and its possible relationship to apoptosis. J Biol Chem 271 18875 18884 [31] Thompson EB 1998 The many roles of c-Myc in apoptosis. Annu Rev Physiol 60 575 600 [32] Huang MJ Cheng YC Liu CR Lin S Liu HE 2006 A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. Exp Hematol 34 1480 1489 [33] Prendergast GC 1999 Mechanisms of apoptosis by c-Myc. Oncogene 18 2967 2987 [34] Jensen JB Parmar M 2006 Strengths and limitations of the neurosphere culture system. Mol Neurobiol 34 153 161 [35] Lapidot T Sirard C Vormoor J Murdoch B Hoang T 1994 A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367 645 648 [36] Bonnet D Dick JE 1997 Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3 730 737 [37] Al-Hajj M Wicha MS Benito-Hernandez A Morrison SJ Clarke MF 2003 Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100 3983 3988 [38] Ricci-Vitiani L Lombardi DG Pilozzi E Biffoni M Todaro M 2007 Identification and expansion of human colon-cancer-initiating cells. Nature 445 111 115 [39] O'Brien CA Pollett A Gallinger S Dick JE 2007 A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445 106 110 [40] Li C Heidt DG Dalerba P Burant CF Zhang L 2007 Identification of pancreatic cancer stem cells. Cancer Res 67 1030 1037 [41] Prince ME Sivanandan R Kaczorowski A Wolf GT Kaplan MJ 2007 Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 104 973 978 [42] Shachaf CM Gentles AJ Elchuri S Sahoo D Soen Y 2008 Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance. Cancer Res 68 5132 5142 [43] Dalerba P Cho RW Clarke MF 2007 Cancer stem cells: models and concepts. Annu Rev Med 58 267 284 [44] Ishikawa F Yoshida S Saito Y Hijikata A Kitamura H 2007 Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 25 1315 1321 [45] Langenau DM Keefe MD Storer NY Guyon JR Kutok JL 2007 Effects of RAS on the genesis of embryonal rhabdomyosarcoma. Genes Dev 21 1382 1395 [46] Zeller KI Zhao X Lee CW Chiu KP Yao F 2006 Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc Natl Acad Sci U S A 103 17834 17839 [47] Daksis JI Lu RY Facchini LM Marhin WW Penn LJ 1994 Myc induces cyclin D1 expression in the absence of de novo protein synthesis and links mitogen-stimulated signal transduction to the cell cycle. Oncogene 9 3635 3645 [48] Gartel AL Ye X Goufman E Shianov P Hay N 2001 Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proc Natl Acad Sci U S A 98 4510 4515 [49] Mitchell KO El-Deiry WS 1999 Overexpression of c-Myc inhibits p21WAF1/CIP1 expression and induces S-phase entry in 12-O-tetradecanoylphorbol-13-acetate (TPA)-sensitive human cancer cells. Cell Growth Differ 10 223 230 [50] Knezevic D Brash DE 2004 Role of E2F1 in apoptosis: a case study in feedback loops. Cell Cycle 3 729 732 [51] Strasser A Harris AW Bath ML Cory S 1990 Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348 331 333 [52] Jacobs JJ Scheijen B Voncken JW Kieboom K Berns A 1999 Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev 13 2678 2690 [53] Eischen CM Weber JD Roussel MF Sherr CJ Cleveland JL 1999 Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 13 2658 2669 [54] Arvanitis C Felsher DW 2006 Conditional transgenic models define how MYC initiates and maintains tumorigenesis. Semin Cancer Biol 16 313 317 [55] Jain M Arvanitis C Chu K Dewey W Leonhardt E 2002 Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 297 102 104 [56] Flores I Murphy DJ Swigart LB Knies U Evan GI 2004 Defining the temporal requirements for Myc in the progression and maintenance of skin neoplasia. Oncogene 23 5923 5930 [57] Shachaf CM Kopelman AM Arvanitis C Karlsson A Beer S 2004 MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 431 1112 1117 [58] Boxer RB Jang JW Sintasath L Chodosh LA 2004 Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell 6 577 586 [59] D'Cruz CM Gunther EJ Boxer RB Hartman JL Sintasath L 2001 c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med 7 235 239 [60] Karlsson A Giuriato S Tang F Fung-Weier J Levan G 2003 Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. Blood 101 2797 2803 [61] Wang H Mannava S Grachtchouk V Zhuang D Soengas MS 2008 c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle. Oncogene 27 1905 1915 [62] Wu CH van Riggelen J Yetil A Fan AC Bachireddy P 2007 Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci U S A 104 13028 13033 [63] Cappellen D Schlange T Bauer M Maurer F Hynes NE 2007 Novel c-MYC target genes mediate differential effects on cell proliferation and migration. EMBO Rep 8 70 76